Major advances in the diagnosis of acute coronary syndromes (ACS) have occurred in 2011, but physicians treating ACS still walk the tightrope between efficacy and bleeding. Key publications have shed light on this delicate balance and heralded a new era of novel oral anticoagulants for the treatment of ACS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mills, N. L. et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 305, 1210–1216 (2011).
Mega, J. L. et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306, 2221–2228 (2011).
Price, M. J. et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097–1105 (2011).
Steg, P. G. et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur. Heart J. 32, 2541–2554 (2011).
Alexander, J. H. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med. 365, 699–708 (2011).
Mega, J. L. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1112277.
Tricoci, P. et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1109719.
Mathews, R. et al. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. Am. J. Cardiol. 107, 1136–1143 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C. P. Cannon has received research grants from Accumentrics, AstraZeneca, GlaxoSmithKline, Intekrin Therapeutics, Merck, and Takeda. He is a member of the advisory board (funds donated to charity) for Alnylam Pharmaceuticals, Bristol-Myers Squibb/Sanofi, and Novartis. He is a clinical advisory with equity in Automedics Medical Systems and has received honorarium for development of independent educational symposia from AstraZeneca and Pfizer. P. Kohli declares no competing interests.
Rights and permissions
About this article
Cite this article
Kohli, P., Cannon, C. Walking the tightrope between efficacy and bleeding. Nat Rev Cardiol 9, 69–71 (2012). https://doi.org/10.1038/nrcardio.2011.206
Published:
Issue date:
DOI: https://doi.org/10.1038/nrcardio.2011.206
